Richard Doubleday Sells 1,635 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at $2,915,496.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Richard Doubleday also recently made the following trade(s):

  • On Wednesday, August 23rd, Richard Doubleday sold 1,635 shares of DexCom stock. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10.

Shares of DexCom, Inc. (DXCM) traded up $0.36 during trading on Friday, reaching $50.74. 1,086,900 shares of the company’s stock traded hands, compared to its average volume of 1,433,733. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $88.80.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/11/richard-doubleday-sells-1635-shares-of-dexcom-inc-dxcm-stock.html.

A number of research firms have weighed in on DXCM. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 price objective (down from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective (down from $85.00) on shares of DexCom in a research note on Thursday, September 28th. Oppenheimer Holdings, Inc. set a $92.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, August 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price objective (down from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Finally, Northland Securities lowered shares of DexCom from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $85.00 to $60.00 in a research note on Thursday, September 28th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $70.69.

Institutional investors and hedge funds have recently made changes to their positions in the company. Advisor Group Inc. lifted its holdings in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after acquiring an additional 837 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after acquiring an additional 568 shares during the last quarter. Toronto Dominion Bank lifted its holdings in shares of DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after acquiring an additional 2,608 shares during the last quarter. Independent Portfolio Consultants Inc. lifted its holdings in shares of DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after acquiring an additional 9 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after acquiring an additional 250 shares during the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply